PROV1IJED. The MIL gene at chromosome band 1 Iq23 is rearranged frequently in de novo and in therapy-related leukemia. The consequence of these translocations is the formation of a chimeric protein that consists of N-terminal sequences from MLL fused in frame to C-terminal sequences of its partner genes. Previous!)', we cloned the ELL gene involved in the (11;19)(q23;pl3.1) translocation, one of the most common of 1 Iq23 aberrations. To characterize these leukemias in detail, we used two alternative strategies to develop mouse models of MLL-ELL leukemia. Using retroviral infection of bone marrow followed by transplantation, recipient mice all develop acute leukemia in 5-6 months. In contrast, in a knock-in model of MI1-ELL generated by gene targeting, chimeric and heterozygous mice do not develop leukemia and exhibit no apparent hematopoietic phenotype, indicating that expression of the Mll-ELL fusion gene is insufficient by itself for the development of acute leukemia. However, treatment of the knock-in mice with ENU induces acute leukemia in 90% of mice that recapitulates the phenotype observed in the retrovira! transplant model and human acute leukemias in patients with (11;19)(q23;pl 3.1) translocations. Recent analyses of blood samples obtained at birth from childhood leukemia patients have revealedthat secondary genetic events are also required in the development of human leukemias. Using the MLL-ELL mouse leukemia models, we propose to use insertional mutagenesis identify the cooperating mutations that are required for the development of MLL-associated leukemia. To determine the critical changes in gene expression that result from the expression of MLL fusion genes, we plan to use microarrays to analyze (low sorted granulocyte/monocyte progenitor cells and myelomonocytic cells obtained from the Mil-Ell knock-in mice before and after treatment with ENU and from mice transplantedwith hematopoietic cell transduced with MLL-ELL. These studies will provide critical reagents for the characterization of 1 Iq23 leukemias, the pathways that cooperate in the development of leukemia, and the development of novel treatment strategies for this common subtype of leukemia.
Showing the most recent 10 out of 20 publications
